FDA
-
-
-
-
-
-
-
Raymond James Positive on Lexeo Therapeutics (LXEO): 'expect shares to trade up'
-
-
-
-
-
-
-
Raymond James Starts Lexeo Therapeutics (LXEO) at Strong Buy, PT $25
-
-
-
-
-
-
-
Lexeo gets FDA breakthrough therapy designation for heart condition drug
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Lexeo Therapeutics (LXEO)
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Lexeo Therapeutics (LXEO)
-
-
-
-
-
-
-
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
-
-
-
-
-
-
-
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
329,987 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

